231,099 Shares in Outset Medical, Inc. $OM Purchased by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC purchased 231,099 shares of Outset Medical, valued at approximately $2.56 million, making up 6.43% of the company's stock as of their latest SEC filing.
• Analyst ratings for Outset Medical vary, with one noting a shift from a "sell" to a "hold" rating, while another firm has rated it as a "strong-buy".
• Outset Medical's stock price is currently around $14.01, well below its one-year high of $25.35, with a market capitalization of $248.96 million.

Parkman Healthcare Partners LLC acquired a new position in shares of Outset Medical, Inc. (NASDAQ:OM - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 231,099 shares of the company's stock, valued at approximately $2,556,000. Parkman Healthcare Partners LLC owned 6.43% of Outset Medical as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of OM. TD Asset Management Inc acquired a new position in Outset Medical during the first quarter worth about $589,000. Squarepoint Ops LLC acquired a new position in Outset Medical during the fourth quarter worth about $174,000. Two Sigma Investments LP raised its stake in Outset Medical by 36.0% during the fourth quarter. Two Sigma Investments LP now owns 488,602 shares of the company's stock worth $542,000 after acquiring an additional 129,334 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Outset Medical during the first quarter worth about $9,293,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Outset Medical during the first quarter worth about $17,730,000.

Analyst Ratings Changes

Several research analysts have commented on the company. Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Scotiabank raised Outset Medical to a "strong-buy" rating in a research note on Thursday, May 15th. Royal Bank Of Canada reissued a "sector perform" rating and set a $22.00 target price on shares of Outset Medical in a research note on Tuesday, August 19th. Finally, BTIG Research set a $37.00 price objective on Outset Medical and gave the company a "buy" rating in a research note on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $24.67.

Outset Medical Stock Performance

Outset Medical stock opened at $14.01 on Friday. The business has a 50 day moving average of $16.18 and a 200-day moving average of $14.71. Outset Medical, Inc. has a 1 year low of $5.85 and a 1 year high of $25.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 7.47 and a quick ratio of 6.05. The company has a market capitalization of $248.96 million, a P/E ratio of -0.69 and a beta of 2.13.

Outset Medical Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

Want to see what other hedge funds are holding OM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Outset Medical, Inc. (NASDAQ:OM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.